Instil Bio, Inc.

TILHealthcare · BiotechnologyVisit siteCIK 0001789769

Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.): $51.4M
Price: $7.58
% Change (Daily % change from the live per-ticker quote feed.): +2.02%
Volume: 9.2K

About

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Quick stats

Shares outstanding6.8M

Computed float3.0M

Float / shares43.9%

Key info

SectorHealthcare

IndustryBiotechnology

CIK0001789769

Websitehttps://instilbio.com

AI Summary

AI-generated

1/6

10d ago

standardmixedearnings

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio reported a cash position of $69.9 million as of June 30, 2026, which management expects to fund the current operating plan into 2028.

Internal development activities have effectively ceased, with in-process R&D expenses dropping to zero and total R&D spending falling approximately 90% year-over-year to $0.3 million.

The company is now actively evaluating potential acquisitions and in-licensing opportunities to identify new therapeutic candidates.

Red flags

In-process R&D expenses were nil for Q2 2026
R&D expenses dropped over 90% year-over-year
Company pivot to M&A/in-licensing due to lack of internal pipeline progress